MedTrace Logo

Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance

NCT00445796 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2008-04-10

No results posted yet for this study

Summary

Primary Objective:

To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on Day 14, of administration of Arsucam® as a single daily intake versus two daily intakes.

Secondary Objective:

To compare the clinical safety of the two treatment regimens.

Conditions

Interventions

DRUG

Artesunate

DRUG

Amodiaquine

Sponsors & Collaborators

Principal Investigators

  • Valérie Lameyre · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30

Countries

  • Cameroon
  • Senegal

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00445796 on ClinicalTrials.gov